The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
Completed
- Conditions
- Depressive Disorder, Major
- Registration Number
- NCT01141400
- Brief Summary
The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured adults on antidepressant therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48865
Inclusion Criteria
- Adult patients (aged 18-64) will be selected from the MarketScan Commercial Database between January 1, 2004, and September 30, 2008, if they have at least two medical claims with a diagnosis of depression and at least one prescription fill for an antidepressant medication.
Exclusion Criteria
- Patients who have any claim with a diagnosis of dementia, schizophrenia, delusional disorder, psychoses, pervasive development disorder, mental retardation, cerebral degenerations, Parkinson's disease, senility, manic depression, bipolar disorder, or major depressive disorder with psychotic symptoms.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is any use of adjunctive treatment (combined and by class) and the time to initiation of adjunctive treatment (combined and by class). 16 months 16 months of medical and prescription drug coverage after the initial antidepressant prescription claim
- Secondary Outcome Measures
Name Time Method sensitivity to cost-sharing will be examined as a function of treatment resistance 16 months 16 months of medical and prescription drug coverage after the initial antidepressant prescription claim